Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
2(18%)
Results Posted
89%(8 trials)

Phase Distribution

Ph phase_3
10
91%

Phase Distribution

0

Early Stage

0

Mid Stage

10

Late Stage

Phase Distribution10 total trials
Phase 3Large-scale testing
10(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(9)

Detailed Status

Completed9
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 310 (100.0%)

Trials by Status

completed982%
active_not_recruiting218%

Recent Activity

2 active trials
Showing 5 of 11
completedphase_3

Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)

NCT04635423
completedphase_3

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

NCT03903562
active_not_recruiting

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

NCT02653118
active_not_recruitingphase_3

Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)

NCT03998254
completedphase_3

A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

NCT00943722
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT04635423Phase 3

Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)

Completed
NCT03903562Phase 3

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

Completed
NCT02653118

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

Active Not Recruiting
NCT03998254Phase 3

Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)

Active Not Recruiting
NCT00943722Phase 3

A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

Completed
NCT03158220Phase 3

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Completed
NCT01304498Phase 3

Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

Completed
NCT00988884Phase 3

A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)

Completed
NCT01254643Phase 3

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

Completed
NCT01047345Phase 3

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Completed
NCT02114385Phase 3

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

Completed

All 11 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
11